Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75years of age with metastatic colorectal cancer

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Munemoto, Yoshinori ^a   Kanda, Mitsuro ^b   Ishibashi, Keiichiro ^c   Hata, Taishi ^d   Kobayashi, Michiya ^e   Hasegawa, Junichi ^f   Fukunaga, Mutsumi ^g   Takagane, Akinori ^h   Otsuji, Toshio ⁱ   Miyake, Yasuhiro ^j   Nagase, Michitaka ^k   Sakamoto, Junichi ^l   Matsuoka, Masaki ^m   Oba, Koji ^n,o   Mishima, Hideyuki ^p  

^a FUKUI KEN SAISEIKAI HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e KOCHI MEDICAL SCHOOL   (Japan)

^f OSAKA ROSAI HOSPITAL   (Japan)

^g Hyogo Prefectural Nishinomiya Hospital   (Japan)

^h HAKODATE GORYOUKAKU HOSPITAL   (Japan)

ⁱ Dongo Hospital   (Japan)

^j Minoh City Hospital   (Japan)

^k GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^l Tokai Central Hospital of Japan Mutual Aid Association of Public School Teachers   (Japan)

^m Matsuoka Clinic   (Japan)

ⁿ UNIVERSITY OF TOKYO   (Japan)

^o UNIVERSITY OF TOKYO   (Japan)

^p AICHI MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

Bevacizumab; Colorectal cancer; Elderly; XELOX

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CREATININE; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

AGED; ALLERGY; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; CANCER REGRESSION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INCIDENCE; INJECTION SITE REACTION; JAPANESE (PEOPLE); LEUKOPENIA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEINURIA; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT FAILURE; VOMITING; AGE; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMICALLY INDUCED; CLINICAL TRIAL; COLORECTAL NEOPLASMS; MORTALITY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; BEVACIZUMAB; CAPECITABINE; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; NAUSEA; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84945134727     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1712-0     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;26:1830-5.
3. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. 1993;306:752-5.
4. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065-75.
5. Venook AND, Lenz H, Innocenti F, Mahoney M, O'Neil B, Shaw J, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol. 2014;32:5s.
6. Kirstein MM, Lange A, Prenzler A, Manns MP, Kubicka S, Vogel A. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. Oncologist. 2014;19:1156-68.
7. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274-81.
8. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45:291-7.
9. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002;13:566-75.
10. Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol. 2002;20:1759-66.
11. Wong NS, Fernando NH, Bendell JC, Morse MA, Blobe GC, Honeycutt W, et al. A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2011;10:210-6.
12. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004;22:2084-91.
13. Makatsoris T, Kalofonos HP, Aravantinos G, Papadimitriou C, Kastritis E, Rigatos SK, et al. A phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancer. Int J Gastrointest Cancer. 2005;35:103-9.
14. Martoni AA, Pinto C, Di Fabio F, Lelli G, Rojas Llimpe FL, Gentile AL, et al. Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial). Eur J Cancer. 2006;42:3161-8.
15. Ducreux M, Bennouna J, Hebbar M, Ychou M, Lledo G, Conroy T, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer. 2011;128:682-90.
16. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23:3706-12.
17. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42.
18. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-44.
19. Groves R. National bibliography of US government publications. Statistical Abstract of the United States: 2008-2011 Washington, DC: US Census Bureau; 2011. 2011 http://www.census.gov/en.html
20. Gallego R, Sanchez N, Maurel J. Chemotherapy for elderly patients with advanced colorectal carcinoma. Expert Rev Anticancer Ther. 2006;6:795-800.
21. Matsumoto T, Nishina T, Mizuta M, Tsuji A, Watanabe R, Takahashi I, et al. Phase II study of first-line chemotherapy with uracil-tegafur plus oral leucovorin in elderly (>/=75years) Japanese patients with metastatic colorectal cancer: SGOSG-CR0501 study. Int J Clin Oncol. 2014.
22. Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14:1077-85.
23. Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011;377:1749-59.
24. Feliu J, Safont MJ, Salud A, Losa F, Garcia-Giron C, Bosch C, et al. Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Br J Cancer. 2010;102:1468-73.
25. Feliu J, Salud A, Escudero P, Lopez-Gomez L, Bolanos M, Galan A, et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70years of age with advanced colorectal cancer. Br J Cancer. 2006;94:969-75.
26. Yoshida M, Muro K, Tsuji A, Hamamoto Y, Yoshino T, Yoshida K, et al. Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial). Eur J Cancer. 2015;51:935-41.
27. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-9.
28. Feliu J, Salud A, Safont MJ, Garcia-Giron C, Aparicio J, Vera R, et al. First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study. Br J Cancer. 2014;111:241-8.
29. McKibbin T, Frei CR, Greene RE, Kwan P, Simon J, Koeller JM. Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting. Oncologist. 2008;13:876-85.
30. Khattak MA, Townsend AR, Beeke C, Karapetis CS, Luke C, Padbury R, et al. Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer. Eur J Cancer. 2012;48:1293-8.
31. Sorbye H, Pfeiffer P, Cavalli-Bjorkman N, Qvortrup C, Holsen MH, Wentzel-Larsen T, et al. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer. 2009;115:4679-87.
32. Oba K, Matsuoka M, Satoh T, Muro K, Oriuchi N, Sakamoto J, et al. Multicentre phase II study of XELOX with bevacizumab in late-stage elderly patients with unresectable advanced/recurrent colorectal cancer: an ASCA study. Jpn J Clin Oncol. 2011;41:134-8.
33. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 2008;26:3523-9.
34. Doi T, Boku N, Kato K, Komatsu Y, Yamaguchi K, Muro K, et al. Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol. 2010;40:913-20.
35. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670-6.
36. Haller DG, Cassidy J, Clarke SJ, Cunningham D, Van Cutsem E, Hoff PM, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol. 2008;26:2118-23.
37. Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol. 2004;15:1330-8.
38. Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, et al. Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. J Clin Oncol. 2014;32:2975-84.